Nimesh Gupta

Last updated
Dr. Nimesh Gupta
Nimesh Gupta.jpg
Born (1980-12-05) December 5, 1980 (age 44)
Known forVirology

Immunology

Vaccinology
Scientific career
Institutions Institute Pasteur, Paris, France

Centre de Recherche des Cordeliers, Paris, France

National Institute of Immunology, India
Website https://www.nimeshlab.com/

Nimesh Gupta, an Indian vaccine immunologist, serves as a Senior Scientist and the Chief of the Vaccine Immunology Laboratory at the National Institute of Immunology, India. [1] [2] He has conducted extensive research on understanding T-cell determinants for long-term and broadly protective immunity against viral infections and vaccinations. In addition to his research work, Gupta has also established a Human Immune Monitoring and T-cell Assay Platform for vaccine evaluation.

Contents

Education and academic posts

Gupta completed his Bachelor of Science in Microbiology and Master of Science in Biotechnology from Jiwaji University, Gwalior. In 2011, he earned his PhD from Jiwaji University in collaboration with DRDO, Gwalior.

In 2008, Gupta attended the Institute Pasteur in Paris, France, for his doctoral studies and was also awarded the Raman-Charpak Fellowship. From 2011, he pursued postdoctoral research under Sebastian Lacroix-Desmazes at the Centre de Recherche des Cordeliers, Paris, focusing on T-cell immunology and immunity to viruses. In 2015, he joined the National Institute of Immunology, India, as a Scientist and established the Vaccine Immunology Laboratory.

Research

Gupta's research primarily focuses on investigating T-cell immunity in the context of viral infections and vaccines. His research programmes involve longitudinal cohort studies on controlled vaccination and human viral infections such as Dengue, Japanese Encephalitis, and COVID-19. In collaboration with AIIMS, Gupta published a report on the immune response to SARS-CoV-2 in the Indian population. [3] The study revealed that, even before the pandemic, the Indian population already possessed cross-reactive T cells to SARS-CoV-2. It also demonstrated that the immune memory response (T cells and B cells) to the virus exhibited durable traits. [4] This research provided critical insights into the type of immunity generated in the Indian population following exposure to SARS-CoV-2.

In 2021, Gupta joined the subgroup of the Vaccine Expert Committee under the Department of Biotechnology to study the immunology of COVID-19 vaccines and infections in India. Through a multi-centre collaboration, he published a report on the characteristics of immune memory responses to inactivated virus vaccines. This study provided evidence on the quality and durability of immune memory established by inactivated virus-based COVID-19 vaccines and their response to SARS-CoV-2 variants. [5]

Gupta's team also contributed significant knowledge on the mechanisms of protective immunity induced by the historical live attenuated Japanese Encephalitis (JE) vaccine (SA14142). [6]

Related Research Articles

In biology, immunity is the state of being insusceptible or resistant to a noxious agent or process, especially a pathogen or infectious disease. Immunity may occur naturally or be produced by prior exposure or immunization.

<span class="mw-page-title-main">Respiratory syncytial virus</span> Species of virus

Respiratory syncytial virus (RSV), also called human respiratory syncytial virus (hRSV) and human orthopneumovirus, is a contagious virus that causes infections of the respiratory tract. It is a negative-sense, single-stranded RNA virus. Its name is derived from the large cells known as syncytia that form when infected cells fuse.

<span class="mw-page-title-main">Japanese encephalitis</span> Infection of the brain caused by the Japanese encephalitis virus

Japanese encephalitis (JE) is an infection of the brain caused by the Japanese encephalitis virus (JEV). While most infections result in little or no symptoms, occasional inflammation of the brain occurs. In these cases, symptoms may include headache, vomiting, fever, confusion and seizures. This occurs about 5 to 15 days after infection.

<span class="mw-page-title-main">Original antigenic sin</span> Immune phenomenon

Original antigenic sin, also known as antigenic imprinting, the Hoskins effect, immunological imprinting, or primary addiction is the propensity of the immune system to preferentially use immunological memory based on a previous infection when a second slightly different version of that foreign pathogen is encountered. This leaves the immune system "trapped" by the first response it has made to each antigen, and unable to mount potentially more effective responses during subsequent infections. Antibodies or T-cells induced during infections with the first variant of the pathogen are subject to repertoire freeze, a form of original antigenic sin.

A breakthrough infection is a case of illness in which a vaccinated individual becomes infected with the illness, because the vaccine has failed to provide complete immunity against the pathogen. Breakthrough infections have been identified in individuals immunized against a variety of diseases including mumps, varicella (Chickenpox), influenza, and COVID-19. The characteristics of the breakthrough infection are dependent on the virus itself. Often, infection of the vaccinated individual results in milder symptoms and shorter duration than if the infection were contracted naturally.

<span class="mw-page-title-main">Antibody-dependent enhancement</span> Antibodies rarely making an infection worse instead of better

Antibody-dependent enhancement (ADE), sometimes less precisely called immune enhancement or disease enhancement, is a phenomenon in which binding of a virus to suboptimal antibodies enhances its entry into host cells, followed by its replication. The suboptimal antibodies can result from natural infection or from vaccination. ADE may cause enhanced respiratory disease, but is not limited to respiratory disease. It has been observed in HIV, RSV, and Dengue virus and is monitored for in vaccine development.

An attenuated vaccine is a vaccine created by reducing the virulence of a pathogen, but still keeping it viable. Attenuation takes an infectious agent and alters it so that it becomes harmless or less virulent. These vaccines contrast to those produced by "killing" the pathogen.

<span class="mw-page-title-main">La Jolla Institute for Immunology</span> Research institute near San Diego, California, U.S.

La Jolla Institute for Immunology (LJI) is a non-profit research organization in La Jolla, a community of San Diego, California. The institute was founded in 1988. It is located in UC San Diego’s Research Park. The institute researches immunology and immune system diseases. The institute employs 220 M.D.s and Ph.D.s, including 23 faculty members and more than 450 employees. Dr. Erica Ollmann Saphire has served as its president and CEO since 2021.

<span class="mw-page-title-main">Vaccine Research Center</span>

The Vaccine Research Center (VRC), is an intramural division of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), US Department of Health and Human Services (HHS). The mission of the VRC is to discover and develop both vaccines and antibody-based products that target infectious diseases.

A subunit vaccine is a vaccine that contains purified parts of the pathogen that are antigenic, or necessary to elicit a protective immune response. Subunit vaccine can be made from dissembled viral particles in cell culture or recombinant DNA expression, in which case it is a recombinant subunit vaccine.

<span class="mw-page-title-main">Inactivated vaccine</span> Vaccine using a killed version of a disease pathogen

An inactivated vaccine is a type of vaccine that contains pathogens that have been killed or rendered inactive, so they cannot replicate or cause disease. In contrast, live vaccines use pathogens that are still alive. Pathogens for inactivated vaccines are grown under controlled conditions and are killed as a means to reduce infectivity and thus prevent infection from the vaccine.

<span class="mw-page-title-main">Akiko Iwasaki</span> Immunobiologist

Akiko Iwasaki is a Sterling Professor of Immunobiology and Molecular, Cellular and Developmental Biology at Yale University. She is also a principal investigator at the Howard Hughes Medical Institute. Her research interests include innate immunity, autophagy, inflammasomes, sexually transmitted infections, herpes simplex virus, human papillomavirus, respiratory virus infections, influenza infection, T cell immunity, commensal bacteria, COVID-19, and long COVID.

Ravindra Kumar Gupta is a professor of clinical microbiology at the Cambridge Institute of Therapeutic Immunology and Infectious Disease at the University of Cambridge. He is also a member of the faculty of the Africa Health Research Institute in Durban, South Africa.

Shane Patrick Crotty is a professor of immunology in the Center for Infectious Disease and Vaccine Research at the La Jolla Institute for Immunology.

Sabra Klein is an American microbiologist who is a Professor of Molecular Microbiology and Immunology at the Johns Hopkins Bloomberg School of Public Health. Her research considers how sex and gender impact the immune system. During the COVID-19 pandemic, Klein investigated why men and women have different COVID-19 outcomes.

A nasal vaccine is a vaccine administered through the nose that stimulates an immune response without an injection. It induces immunity through the inner surface of the nose, a surface that naturally comes in contact with many airborne microbes. Nasal vaccines are emerging as an alternative to injectable vaccines because they do not use needles and can be introduced through the mucosal route. Nasal vaccines can be delivered through nasal sprays to prevent respiratory infections, such as influenza.

<span class="mw-page-title-main">Weatherall Institute of Molecular Medicine</span> British medical research institute

The MRC Weatherall Institute of Molecular Medicine at the University of Oxford is a research institute located at the John Radcliffe Hospital in Oxford. Founded in 1989 by Sir David Weatherall, the institute focuses on furthering our understanding of clinical medicine at a molecular level. It was one of the first institutes of its kind in the world to be dedicated to research in this area.

<span class="mw-page-title-main">Covaxin</span> Vaccine against COVID-19

Covaxin is a whole inactivated virus-based COVID-19 vaccine developed by Bharat Biotech in collaboration with the Indian Council of Medical Research - National Institute of Virology.

<span class="mw-page-title-main">Viral vector vaccine</span> Type of vaccine

A viral vector vaccine is a vaccine that uses a viral vector to deliver genetic material (DNA) that can be transcribed by the recipient's host cells as mRNA coding for a desired protein, or antigen, to elicit an immune response. As of April 2021, six viral vector vaccines, four COVID-19 vaccines and two Ebola vaccines, have been authorized for use in humans.

<span class="mw-page-title-main">Eui-Cheol Shin</span> South Korean immunologist (born 1971)

Eui-Cheol Shin is a South Korean medical immunologist, academic, and author. He is a professor at the Graduate School of Medical Science and Engineering at the Korea Advanced Institute of Science and Technology (KAIST), and director of The Center for Viral Immunology at the Institute for Basic Science (IBS), a Korean government-funded research institute.

References

  1. "Dr. Nimesh Gupta | National Institute of Immunology (NII)". www.nii.res.in. Retrieved 2024-12-23.
  2. "Nimesh GUPTA". in.linkedin.com.
  3. "AIIMS - All India Institute Of Medical Science". www.aiims.edu. Retrieved 2024-12-23.
  4. Ansari, Asgar; Arya, Rakesh; Sachan, Shilpa; Jha, Someshwar Nath; Kalia, Anurag; Lall, Anupam; Sette, Alessandro; Grifoni, Alba; Weiskopf, Daniela; Coshic, Poonam; Sharma, Ashok; Gupta, Nimesh (2021). "Immune Memory in Mild COVID-19 Patients and Unexposed Donors Reveals Persistent T Cell Responses After SARS-CoV-2 Infection". Frontiers in Immunology. 12: 636768. doi: 10.3389/fimmu.2021.636768 . ISSN   1664-3224. PMC   7991090 . PMID   33777028.
  5. Vikkurthi, Rajesh; Ansari, Asgar; Pai, Anupama R.; Jha, Someshwar Nath; Sachan, Shilpa; Pandit, Suvechchha; Nikam, Bhushan; Kalia, Anurag; Jit, Bimal Prasad; Parray, Hilal Ahmad; Singh, Savita; Kshetrapal, Pallavi; Wadhwa, Nitya; Shrivastava, Tripti; Coshic, Poonam (July 2022). "Inactivated whole-virion vaccine BBV152/Covaxin elicits robust cellular immune memory to SARS-CoV-2 and variants of concern". Nature Microbiology. 7 (7): 974–985. doi: 10.1038/s41564-022-01161-5 . ISSN   2058-5276. PMID   35681012. S2CID   249543586.
  6. Kalia, Anurag; Agrawal, Mona; Gupta, Nimesh (2021). "CD8+ T cells are crucial for humoral immunity establishment by SA14-14-2 live attenuated Japanese encephalitis vaccine in mice". European Journal of Immunology. 51 (2): 368–379. doi: 10.1002/eji.202048745 . ISSN   1521-4141. PMID   32749679. S2CID   225366194.